Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 203
   

Global Markets Direct’s, ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015’, provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 9
Therapeutics Development 10
Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Overview 10
Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis 11
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Development by Companies 12
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 14
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Development by Companies 18
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Investigation by Universities/Institutes 22
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Companies Involved in Therapeutics Development 23
Absynth Biologics Limited 23
Actelion Ltd 24
Adenium Biotech ApS 25
AIMM Therapeutics B.V. 26
Akthelia pharmaceuticals ehf 27
AmpliPhi Biosciences Corporation 28
Angothera GmbH 29
Assembly Biosciences, Inc. 30
AvidBiotics Corp. 31
C3 Jian, Inc 32
Daiichi Sankyo Company, Limited 33
Evec, Inc. 34
GangaGen Inc. 35
ImmunoBiology Limited 36
Immuron Limited 37
Inovio Pharmaceuticals, Inc. 38
Intrexon Corporation 39
MedImmune, LLC 40
Merck & Co., Inc. 41
MGB Biopharma Limited 42
Microbiotix, Inc. 43
Micropharm Limited 44
Morphochem AG 45
Nanotherapeutics, Inc. 46
Novabiotics Limited 47
NovoBiotic Pharmaceuticals, LLC 48
Oragenics, Inc. 49
Pfizer Inc. 50
Procarta Biosystems Ltd 51
Prokarium Limited 52
Rebiotix Inc. 53
Sanofi Pasteur SA 54
Sarum Biosciences Limited 55
Sequella, Inc. 56
Seres Therapeutics, Inc. 57
Shire Plc 58
Sorrento Therapeutics, Inc. 59
Stellar Biotechnologies, Inc. 60
Summit Therapeutics Plc 61
Synthetic Biologics, Inc. 62
Valevia UK Limited 63
Valneva SE 64
VaxInnate Corporation 65
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 70
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(actoxumab + bezlotoxumab) - Drug Profile 76
ABCD-01 - Drug Profile 77
actoxumab - Drug Profile 78
AKT-10081 - Drug Profile 79
Antibodies for Enterocolitis - Drug Profile 80
AP-114 - Drug Profile 81
AvR2-V10 - Drug Profile 82
bezlotoxumab - Drug Profile 84
Biologic for Clostridium Difficile Enteropathy - Drug Profile 85
Biologic for Clostridium difficile Infections - Drug Profile 86
C-3CD17 - Drug Profile 87
cadazolid - Drug Profile 88
Cdiff snare - Drug Profile 89
clostridium difficile vaccine - Drug Profile 90
Clostridium difficile vaccine - Drug Profile 91
clostridium difficile vaccine - Drug Profile 92
Clostridium difficile vaccine - Drug Profile 93
clostridium difficile vaccine - Drug Profile 94
Clostridium difficile vaccine - Drug Profile 95
Clostridium difficile vaccine - Drug Profile 96
Clostridium difficile vaccine - Drug Profile 97
clostridium difficile vaccine - Drug Profile 98
CRS-3123 - Drug Profile 99
Drug for Clostridium difficile Infection - Drug Profile 100
Endolysin - Drug Profile 101
EV-029104 - Drug Profile 103
EV-029105A - Drug Profile 104
fidaxomicin - Drug Profile 105
GBV-006 - Drug Profile 108
IMM-529 - Drug Profile 109
INS-001 - Drug Profile 110
INX-201 - Drug Profile 111
MB-101 - Drug Profile 112
MBX-500 - Drug Profile 113
MCB-3681 - Drug Profile 115
MGBBP-3 - Drug Profile 116
Monoclonal Antibodies for Clostridium difficile - Drug Profile 118
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 119
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 120
MU-1140 - Drug Profile 121
NP-432 - Drug Profile 123
OraCAb - Drug Profile 124
P-2-A - Drug Profile 125
P-4A - Drug Profile 126
PF-06425090 - Drug Profile 127
PolyCAb - Drug Profile 128
PRO-391 - Drug Profile 129
ramoplanin - Drug Profile 130
RBX-2660 - Drug Profile 131
ridinilazole - Drug Profile 133
SER-109 - Drug Profile 135
SER-262 - Drug Profile 136
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile 137
Small Molecules for Clostridium Difficile Infections - Drug Profile 138
Small Molecules for Clostridium Difficile Infections - Drug Profile 139
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 140
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 141
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 143
SMT-21829 - Drug Profile 144
SQ-109 - Drug Profile 145
SQ-641 - Drug Profile 149
surotomycin - Drug Profile 150
SYN-004 - Drug Profile 151
VAL-301 - Drug Profile 152
VLA-84 - Drug Profile 154
VP-20621 - Drug Profile 156
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Recent Pipeline Updates 157
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects 186
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products 187
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Product Development Milestones 188
Featured News & Press Releases 188
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015 15
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 17
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Late Stage Development, H2 2015 20
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Development, H2 2015 22
Products under Development by Companies, H2 2015 23
Products under Development by Companies, H2 2015 (Contd..1) 24
Products under Development by Companies, H2 2015 (Contd..2) 25
Products under Development by Companies, H2 2015 (Contd..3) 26
Products under Investigation by Universities/Institutes, H2 2015 27
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2015 28
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2015 29
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2015 30
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2015 31
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Akthelia pharmaceuticals ehf, H2 2015 32
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2015 33
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2015 34
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H2 2015 35
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2015 36
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2015 37
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 38
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Evec, Inc., H2 2015 39
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2015 40
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2015 41
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Immuron Limited, H2 2015 42
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 43
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Intrexon Corporation, H2 2015 44
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2015 45
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2015 46
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2015 47
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2015 48
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2015 49
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Morphochem AG, H2 2015 50
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2015 51
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2015 52
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015 53
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2015 54
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2015 55
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Procarta Biosystems Ltd, H2 2015 56
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2015 57
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2015 58
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2015 59
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sarum Biosciences Limited, H2 2015 60
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sequella, Inc., H2 2015 61
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2015 62
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Shire Plc, H2 2015 63
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2015 64
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2015 65
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2015 66
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2015 67
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2015 68
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valneva SE, H2 2015 69
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by VaxInnate Corporation, H2 2015 70
Assessment by Monotherapy Products, H2 2015 71
Assessment by Combination Products, H2 2015 72
Number of Products by Stage and Target, H2 2015 74
Number of Products by Stage and Mechanism of Action, H2 2015 76
Number of Products by Stage and Route of Administration, H2 2015 78
Number of Products by Stage and Molecule Type, H2 2015 80
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H2 2015 162
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects, H2 2015 191
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products, H2 2015 192

List of Figures

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015 15
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 17
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Products, H2 2015 22
Assessment by Monotherapy Products, H2 2015 71
Number of Products by Top 10 Targets, H2 2015 73
Number of Products by Stage and Top 10 Targets, H2 2015 73
Number of Products by Top 10 Mechanism of Actions, H2 2015 75
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 75
Number of Products by Routes of Administration, H2 2015 77
Number of Products by Stage and Routes of Administration, H2 2015 77
Number of Products by Top 10 Molecule Types, H2 2015 79
Number of Products by Stage and Top 10 Molecule Types, H2 2015 79

Published By: Global Markets Direct
Product Code: Global Markets Direct13360


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: